Ajanta Pharma
2,546.60
+0.90(+0.04%)
Market Cap₹31,810.12 Cr
PE Ratio34.53
IndustryHealthcare
Company Performance:
1D+0.04%
1M-2.02%
6M-11.16%
1Y+8.79%
5Y+162.76%
View Company Insightsright
Latest news about Ajanta Pharma
Ajanta Pharma Q4 FY25: Revenue Grows, Margins Shrink Amid Market Challenges May 02, 2025
Ajanta Pharma's Q4 FY25 results show 11% YoY revenue growth to Rs 11.70 billion and 11.10% PAT increase to Rs 2.30 billion. EBITDA grew 6.80% YoY to Rs 2.97 billion, but margins contracted. Systematix maintains 'Buy' rating with revised target price. Results published in Business Standard and Navakal on May 1, 2025.
Ajanta Pharma Reports 11% Growth in Q4 Profit and Revenue, Margin Contracts Apr 30, 2025
Ajanta Pharma Joins FTSE All World Index, Expands Manufacturing Capacity Mar 21, 2025
Ajanta Pharma to Invest ₹92 Crore in Pithampur Facility Expansion Mar 20, 2025